SCHEMBL6499896

SCHEMBL6499896

COC(=O)c1cc(C)c2nc(C)n(Cc3ccc(N(C)C(=O)OC(C)(C)C)cc3Cl)c2n1

nearest known ligand 0.38

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
NQO2 P16083 1/20 0.35
HSD17B13 Q7Z5P4 5/20 0.34
MEN1 O00255 1/20 0.33
NPC1 O15118 1/20 0.33
RAB9A P51151 1/20 0.33
KMT2A Q03164 1/20 0.33
MAPT P10636 4/20 0.33
DCTPP1 Q9H773 1/20 0.33
PIK3CB P42338 2/20 0.33
KAT8 Q9H7Z6 2/20 0.32
KAT6A Q92794 1/20 0.32
KAT5 Q92993 1/20 0.32
TP53 P04637 2/20 0.32
TLR7 Q9NYK1 1/20 0.32
ALDH1A1 P00352 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31
P2RX3 P56373 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6500370 0.91 PIK3CB (0.37) HSD17B13NPC1MAPTPIK3CBKAT8
SCHEMBL6499901 0.90 HSD17B13 (0.33) NQO2HSD17B13MEN1NPC1RAB9A
SCHEMBL6491418 0.87 MAPT (0.37) NQO2MEN1NPC1RAB9AKMT2A
SCHEMBL6501679 0.85 KAT8 (0.39) HSD17B13RAB9AKAT8KAT6AKAT5
SCHEMBL6497677 0.83 PPARG (0.47)
SCHEMBL6495100 0.82 MAPT (0.35) NQO2MEN1NPC1RAB9AKMT2A
SCHEMBL6499909 0.81 PIK3CB (0.36) HSD17B13MAPTPIK3CBALDH1A1SMN1; SMN2
SCHEMBL6491019 0.81 DCTPP1 (0.38) HSD17B13MEN1NPC1RAB9AKMT2A
SCHEMBL6503105 0.80 ALDH1A1 (0.38) NPC1KMT2AMAPTPIK3CBKAT8
SCHEMBL6299229 0.80 MAPT (0.39) MEN1NPC1RAB9AKMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6890934-B2 Sulfonamide compounds and uses thereof as medicines FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2005-05-10 US disclosed
US-20030171396-A1 Sulfonamide compounds and uses thereof as medicines FUJISAWA PHARMACEUTICAL CO. LTD. (JP) 2003-09-11 US disclosed
US-6573274-B1 Treatment of the diseases curable based on a hypoglycemic action, and the diseases curable based on a cGMP-PDE inhibitory action, a smooth muscle relaxing action, a bronchodilating action, a vasodilating action, a smooth muscle FUJISAWA PHARMACEUTICAL CO. LTD. (JP) 2003-06-03 US disclosed
EP-1136492-A1 SULFONAMIDE COMPOUNDS AND USES THEREOF AS MEDICINES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2001-09-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030171396-A1 Sulfonamide compounds and uses thereof as medicines PDE2A, PDE3A, PDE5A NQO2 1083/4885HSD17B13 2027/4885MEN1 2819/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.